KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
41 hedge funds and large institutions have $84.1M invested in KalVista Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
44.71% more ownership
Funds ownership: 0% → 44.71% (+45%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$19.9M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$10.8M |
| 4 |
BC
Broadfin Capital
New York
|
+$8.36M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$4.5M |
Top Sellers
KALV Hedge Fund Activity: Q2 2015 in Review
41 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2015, worth a combined $84.1M.
Buyers outnumbered sellers: 41 funds opened new KALV positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $23.4M.
- 41 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $84.1M of KalVista Pharmaceuticals stock for Q2 2015.
- 41 funds opened new KalVista Pharmaceuticals positions in Q2 2015 and 0 closed out, a net change of +41 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $23.4M added.
Based on aggregated 13F filings for Q2 2015.